EW

Edwards Lifesciences Corp. - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Edwards Lifesciences is a global leader in structural heart disease innovation, operating in four geographic segments: United States, Europe, Japan, and Rest of World. The company's product portfolio includes Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical products. The company recently completed the acquisition of Autus Valve Technologies, Inc. in February 2026 and continues to manage transition services related to the prior sale of its Critical Care product group.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 16.7% year-over-year, driven by strong performance in TAVR (+14.4%) and TMTT (+51.9%) product lines. International sales grew 23.9%, aided by favorable foreign currency fluctuations.
• Operating Expenses: SG&A expenses rose to $522.2 million (from $465.7 million) due to higher headcount and foreign currency impacts. R&D expenses increased to $263.3 million (from $254.6 million) reflecting investments in heart failure management.
• Unusual Items:
  • Impairment Loss: A non-cash impairment charge of $123.6 million was recorded related to a Variable Interest Entity (VIE) investment where the carrying amount was deemed unrecoverable.
  • Acquisition Gain: A $65.2 million gain was recognized from the remeasurement of a previously held interest upon the acquisition of Autus Valve Technologies.
  • Litigation: Certain litigation expenses increased significantly to $37.1 million (from $10.9 million) due to ongoing legal proceedings and tax disputes.
• Cash Flow: Operating cash flow decreased significantly to $43.8 million (from $280.4 million) primarily due to higher working capital needs, despite improved operating performance.

Guidance, Outlook, and Risks

Management Commentary: Management highlighted robust growth in TAVR and TMTT sales. The acquisition of Autus adds a pipeline for pediatric pulmonary heart valves. The company expects the OECD Pillar Two global minimum tax rules to result in approximately $70.0 million in additional tax expense for 2026 prior to offsets.

Risks and Contingencies:

• Tax Disputes: Significant uncertainty remains regarding IRS examinations for tax years 2015-2020. The IRS has issued draft Notices of Proposed Adjustment (NOPAs) proposing substantial increases to taxable income. The company intends to contest these through judicial processes.
• Legal Proceedings: The company faces patent infringement lawsuits (e.g., Aortic Innovations, Cardiovalve) and shareholder derivative actions. While management does not believe current accruals will have a material adverse effect on overall financial condition, resolution could impact specific periods.
• Trade Policy: Potential impacts from U.S. trade policy changes, including tariffs, could affect costs and demand.

Investor Verification Checklist

• Impairment Details: Verify the specific nature of the $123.6 million VIE impairment and the likelihood of future similar charges.
• Tax Liability Exposure: Review the status of the IRS Draft NOPAs and the company's legal strategy regarding the $269.3 million notice of deficiency and new proposed adjustments.
• Working Capital Trends: Analyze the drivers behind the sharp decline in operating cash flow and the increase in accounts receivable and inventory.
• Acquisition Integration: Monitor the integration of Autus Valve Technologies and the potential for future contingent consideration payments (up to $132.5 million).
• Share Repurchases: Confirm the remaining $1.5 billion authorization under the share repurchase program and the impact of the recent $500 million accelerated share repurchase (ASR).